Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Catenae Innovation Plc LSE:CTEA London Ordinary Share GB00BKM6CG53 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 3.05 2.90 3.20 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 0.1 -1.0 -3.0 - 7

Catenae Innovation PLC Joint Venture with Blackhive Africa Medical

16/10/2020 7:00am

UK Regulatory (RNS & others)


Catenae Innovation (LSE:CTEA)
Historical Stock Chart


From Sep 2020 to Oct 2020

Click Here for more Catenae Innovation Charts.

TIDMCTEA

RNS Number : 2706C

Catenae Innovation PLC

16 October 2020

16 October 2020

Catenae Innovation PLC

("Catenae", the "Company" or the "Group")

Catenae signs Joint Venture with Blackhive Africa Medical

Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of digital media and technology, announces that it has signed a 50/50 Joint Venture agreement ("JV") through Onside Now Limited, the joint venture entity, with BHA-Medical Limited and BHA-Medical (Pty) Limited, respectively UK and South African entities of the medical equipment supply company, Blackhive Africa Medical ("BHA-Medical"), to deliver an integrated Covid-19 'Test, Monitor, Manage Programme' which has the potential for use and deployment by governments, businesses and organisations.

To date BHA-Medical has supplied approximately 350,000 CE-certified Covid-19 Near-Patient Three-Antibody Tests to businesses within the UK, including to two FTSE 100 companies.

BHA-Medical will provide the JV with the Near-Patient Covid-19 Healgen Antigen Test scientifically validated by the UK Government, an oral and nasal swab test which detects current Covid-19 infection, as well as the Near-Patient Three-Antibody Test, for which BHA-Medical has exclusivity in the UK to detect current and historic symptomatic and asymptomatic Covid-19 cases using a finger prick blood sample. Both tests are conducted on site by clinically trained professionals and deliver results in around twenty minutes.

Any profits generated through the JV will be distributed evenly to BHA Medical and Catenae. There is no guarantee that the JV will generate profits. The Company will update the market with developments at the JV in due course.

Catenae's technology solutions allow for the inputting of the Covid-19 test results into the Company's GDPR-compliant data management platform utilising the Company's distributed ledger technology (blockchain). Administrators of the platform will have access to a 'Data Intelligence Dashboard' in order to monitor the health status of their populations and respond to outbreaks and hotspots of Covid-19 infections.

In addition, where needed, individuals who have taken either of the above Covid-19 test are able to download Catenae's proprietary Onsite ID mobile app whereby their Covid-19 test status can be disclosed in a secure digital medium. Their test result can also be sent to them via the platform's 'Push notification' functionality.

Guy Meyer, Chief Executive Officer of Catenae, said: "We are pleased to have entered into a Joint Venture agreement with BHA-Medical both here in the U.K. and in South Africa. BHA-Medical and ourselves are strategically aligned given that we complement each other's offering. Our revenue models are both volume based and both have the capacity to scale. BHA-Medical's presence in South Africa also dovetails into the current market activity that Afrik-ID are undertaking across the SADC region from neighbouring Botswana.

"We are committed to providing the technology and software required to help governments, businesses and organisations safely and securely monitor and manage their populations during these difficult times.

"We look forward to updating the market as the JV progresses."

Gavyn Hough, Group Director of BHA-Medical, said: "BHA-Medical is a global supplier of medical equipment and consumables. Recently, our team has dedicated itself almost entirely to supporting the fight against Covid-19. BHA-Medical is bringing the latest near-patient testing technology to our clients, enabling cases to be identified faster, tracing procedures to be initiated faster, staff kept safe and lives saved. Working in partnership with Catenae will provide individuals, organisations and governments with real-time health data, which, when coupled with the latest BHA-Medical testing technology, will create Covid-19 confidence and the safest possible environments."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged for release of this announcement on behalf of the Company was Guy Meyer, Chief Executive Officer of the Company.

- Ends -

For further information please contact:

 
                                       +44 (0)191 580 
 Catenae Innovation PLC                          8545 
 Guy Meyer, Chief Executive Officer 
 
 
 Cairn Financial Advisers LLP (Nominated Adviser)    +44(0)20 7213 0880 
 Liam Murray / Jo Turner 
 
                                                         +44 (0)20 3463 
 Brandon Hill Capital Limited, Broker                              5000 
 Andy Gutmann 
 
                                                         +44 (0)20 3004 
 Yellow Jersey PR (PR & IP)                                        9512 
 Sarah Hollins / Annabel Atkins 
 

Notes to Editors:

About the Joint Venture

www.catenaeinnovation.com/bha-medical-joint-venture

About Catenae Innovation PLC

Catenae Innovation is an AIM quoted provider of digital media and technology services. Catenae use the power of blockchain to deliver solutions where its people-centric technology enables trust and certainty allowing organisations to gain better control over their operations, manage staff and safely welcome customers.

www.catenaeinnovation.com

About BHA-Medical

BHA-Medical is a medical equipment supply company, with over 20 years of international experience. It works commercially and clinically with some of the world leaders in both pre-hospital and hospital settings.

www.bha-medical.com

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

JVEUVAURRVURAUA

(END) Dow Jones Newswires

October 16, 2020 02:00 ET (06:00 GMT)

1 Year Catenae Innovation Chart

1 Year Catenae Innovation Chart

1 Month Catenae Innovation Chart

1 Month Catenae Innovation Chart
ADVFN Advertorial
Your Recent History
LSE
CTEA
Catenae In..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201020 06:12:00